[1]
Kadono, Y., Kawaguchi, S., Nohara, T., Shigehara, K., Izumi, K., Kamijima, T., Seto, C., Takano, A., Yotsuyanagi, S., Nakagawa, R., Miyagi, T., Aoyama, S., Asahi, H., Fukuda, R. and Mizokami, A. 2021. Favorable Response of Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma with Only Small Lesions to not be Considered Measurable by RECIST. Urology Journal. 19, 03 (Dec. 2021), 202-208. DOI:https://doi.org/10.22037/uj.v18i.6652.